patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_441211 | REC_0015301 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 9.6 | 55 | male | 1 | 11 | 5 | 4 | pembrolizumab 200 mg q3w | 12.1 | true | MSS | 2026-03-15T05:36:01.155496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172323 | REC_0015302 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 7 | 62 | male | 1 | 54 | 8.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.5 | true | MSS | 2026-03-15T05:36:01.156364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391351 | REC_0015303 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16 | 70 | female | 3 | 6 | 3.2 | 1 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:36:01.156868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955442 | REC_0015304 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 4.3 | 60 | female | 1 | 25 | 7.4 | 10 | sotorasib 960 mg daily | 14.6 | true | MSS | 2026-03-15T05:36:01.157280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923594 | REC_0015305 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 3.3 | 65 | male | 1 | 8 | 4.4 | 2 | entrectinib 600 mg daily | 16.3 | true | MSS | 2026-03-15T05:36:01.157903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222448 | REC_0015306 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.3 | 65 | female | 1 | 26 | 7.5 | 5 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:36:01.158379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177973 | REC_0015307 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.3 | 70 | female | 0 | 72 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:01.158773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339763 | REC_0015308 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 8.1 | 72 | female | 1 | 14 | 4.3 | 4 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:36:01.159176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426471 | REC_0015309 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.5 | 74 | female | 1 | 14 | 6.3 | 4 | entrectinib 600 mg daily | 10 | false | MSI-H | 2026-03-15T05:36:01.159593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232317 | REC_0015310 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.3 | 73 | female | 1 | 16 | 6 | 6 | pembrolizumab 200 mg q3w | 9 | true | MSS | 2026-03-15T05:36:01.159981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679365 | REC_0015311 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.9 | 55 | male | 0 | 31 | 5.3 | 5 | pembrolizumab 200 mg q3w | 6.5 | false | MSS | 2026-03-15T05:36:01.160426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744924 | REC_0015312 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 8.5 | 62 | female | 1 | 81 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:36:01.160834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479000 | REC_0015313 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.3 | 67 | female | 0 | 82 | 5.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:01.161227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171371 | REC_0015314 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.7 | 75 | female | 1 | 0 | 5.7 | 5 | alectinib 600 mg BID | 18.9 | false | MSI-H | 2026-03-15T05:36:01.161587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242685 | REC_0015315 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 8.7 | 63 | female | 0 | 23 | 5.6 | 4 | entrectinib 600 mg daily | 8 | false | MSS | 2026-03-15T05:36:01.162191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131171 | REC_0015316 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 8.8 | 75 | female | 1 | 7 | 5 | 2 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:36:01.162653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505815 | REC_0015317 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 11.8 | 77 | male | 1 | 21 | 4.2 | 1 | osimertinib 80 mg daily | 22.1 | false | MSS | 2026-03-15T05:36:01.163134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223614 | REC_0015318 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.9 | 64 | male | 0 | 8 | 4.8 | 6 | entrectinib 600 mg daily | 10.6 | false | MSI-H | 2026-03-15T05:36:01.163562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980006 | REC_0015319 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 14 | 19.2 | 75 | male | 1 | 18 | 5.5 | 6 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:36:01.163986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985716 | REC_0015320 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 10.3 | 59 | male | 1 | 12 | 6.6 | 5 | alectinib 600 mg BID | 12.2 | true | MSS | 2026-03-15T05:36:01.172334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415165 | REC_0015321 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 12.5 | 63 | female | 1 | 7 | 4.3 | 2 | osimertinib 80 mg daily | 19.2 | false | MSI-H | 2026-03-15T05:36:01.172818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985341 | REC_0015322 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 15.5 | 63 | female | 0 | 22 | 5.9 | 0 | sotorasib 960 mg daily | 40.5 | false | MSI-H | 2026-03-15T05:36:01.173224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232215 | REC_0015323 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 8.6 | 54 | female | 0 | 27 | 4.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.2 | false | MSS | 2026-03-15T05:36:01.173606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990598 | REC_0015324 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.2 | 70 | male | 1 | 17 | 5.1 | 1 | sotorasib 960 mg daily | 18.7 | false | MSI-H | 2026-03-15T05:36:01.174020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268429 | REC_0015325 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 33 | 2.3 | 76 | male | 2 | 14 | 4.9 | 2 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:36:01.174413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968136 | REC_0015326 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.6 | 71 | male | 2 | 54 | 4.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:36:01.174784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219548 | REC_0015327 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 14 | 8.8 | 76 | female | 1 | 39 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:36:01.175153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260953 | REC_0015328 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 7.6 | 60 | female | 0 | 12 | 6.7 | 5 | pembrolizumab 200 mg q3w | 11.4 | true | MSS | 2026-03-15T05:36:01.175920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991847 | REC_0015329 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 5 | 67 | female | 0 | 17 | 5.8 | 6 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:36:01.176508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941527 | REC_0015330 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.5 | 76 | male | 2 | 41 | 5.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.1 | true | MSS | 2026-03-15T05:36:01.176932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561715 | REC_0015331 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 4.2 | 69 | female | 1 | 20 | 6.3 | 5 | entrectinib 600 mg daily | 13.5 | true | MSS | 2026-03-15T05:36:01.177308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289191 | REC_0015332 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.4 | 59 | female | 1 | 8 | 8.6 | 3 | sotorasib 960 mg daily | 14.6 | true | MSI-H | 2026-03-15T05:36:01.177690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213568 | REC_0015333 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.2 | 75 | female | 3 | 15 | 6.4 | 7 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.178097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493848 | REC_0015334 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 2.1 | 70 | female | 1 | 13 | 5.7 | 1 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:36:01.178486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335641 | REC_0015335 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6 | 53 | female | 0 | 62 | 3.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:36:01.178863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501877 | REC_0015336 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.6 | 70 | female | 1 | 42 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:36:01.179270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287948 | REC_0015337 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 12.9 | 62 | female | 0 | 15 | 5.6 | 7 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:36:01.179672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395640 | REC_0015338 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 7.2 | 63 | female | 1 | 16 | 6.5 | 2 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:36:01.184191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314918 | REC_0015339 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.4 | 63 | male | 0 | 28 | 6 | 7 | alectinib 600 mg BID | 7.3 | false | MSS | 2026-03-15T05:36:01.184898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722628 | REC_0015340 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 14.5 | 65 | female | 0 | 17 | 5.3 | 8 | osimertinib 80 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:36:01.187943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139930 | REC_0015341 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 6.1 | 69 | female | 1 | 17 | 4.8 | 7 | sotorasib 960 mg daily | 11.4 | false | MSS | 2026-03-15T05:36:01.188813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724261 | REC_0015342 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.1 | 68 | female | 1 | 19 | 5.9 | 7 | entrectinib 600 mg daily | 9.5 | true | MSS | 2026-03-15T05:36:01.189342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778441 | REC_0015343 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 16.3 | 82 | female | 2 | 7 | 5.6 | 1 | osimertinib 80 mg daily | 21 | false | MSS | 2026-03-15T05:36:01.189765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504022 | REC_0015344 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 14.7 | 58 | male | 1 | 9 | 4.9 | 3 | alectinib 600 mg BID | 23.7 | true | MSS | 2026-03-15T05:36:01.190181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132430 | REC_0015345 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 17.7 | 54 | male | 0 | 13 | 4.5 | 0 | osimertinib 80 mg daily | 24.4 | false | MSS | 2026-03-15T05:36:01.190596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722301 | REC_0015346 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.7 | 58 | female | 0 | 10 | 5.3 | 4 | sotorasib 960 mg daily | 11.1 | true | MSS | 2026-03-15T05:36:01.190985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926387 | REC_0015347 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 13 | 14 | 61 | male | 0 | 12 | 7.8 | 6 | sotorasib 960 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:36:01.191372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833318 | REC_0015348 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.4 | 68 | female | 1 | 8 | 5.8 | 7 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:01.191772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377526 | REC_0015349 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 14 | 62 | female | 0 | 22 | 5.5 | 1 | alectinib 600 mg BID | 19.5 | true | MSI-H | 2026-03-15T05:36:01.192848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880122 | REC_0015350 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11 | 63 | female | 0 | 2 | 7 | 1 | osimertinib 80 mg daily | 15.6 | true | MSS | 2026-03-15T05:36:01.193387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141595 | REC_0015351 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 7.8 | 87 | female | 1 | 9 | 5.4 | 0 | osimertinib 80 mg daily | 49.1 | false | MSS | 2026-03-15T05:36:01.193795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337078 | REC_0015352 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 11.4 | 63 | male | 0 | 10 | 4.5 | 0 | osimertinib 80 mg daily | 31.1 | true | MSS | 2026-03-15T05:36:01.194195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652161 | REC_0015353 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.8 | 72 | female | 1 | 15 | 6 | 1 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:36:01.194588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535347 | REC_0015354 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 9.4 | 78 | female | 1 | 19 | 6.2 | 6 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:01.195186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640437 | REC_0015355 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.2 | 67 | female | 1 | 1 | 7 | 4 | osimertinib 80 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:36:01.195614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134873 | REC_0015356 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.4 | 59 | male | 1 | 8 | 4.9 | 1 | entrectinib 600 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:01.196013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190811 | REC_0015357 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.1 | 80 | male | 1 | 44 | 6.5 | 4 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:36:01.196581+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946891 | REC_0015358 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 11 | 67 | male | 0 | 21 | 6.2 | 7 | osimertinib 80 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:36:01.197013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773587 | REC_0015359 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.1 | 49 | male | 0 | 21 | 6.8 | 7 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:01.197414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171105 | REC_0015360 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 16.7 | 71 | female | 1 | 27 | 5.7 | 2 | osimertinib 80 mg daily | 36 | false | MSI-H | 2026-03-15T05:36:01.197793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888889 | REC_0015361 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 15.4 | 70 | female | 1 | 9 | 6.5 | 2 | entrectinib 600 mg daily | 5.2 | false | MSS | 2026-03-15T05:36:01.198149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254345 | REC_0015362 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.7 | 73 | female | 1 | 21 | 6.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:36:01.198552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413780 | REC_0015363 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.2 | 59 | female | 1 | 15 | 3.5 | 4 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:01.198961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573662 | REC_0015364 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 13.1 | 60 | male | 1 | 11 | 6.7 | 5 | entrectinib 600 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:36:01.199352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100038 | REC_0015365 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.3 | 63 | male | 1 | 29 | 5.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.3 | false | MSS | 2026-03-15T05:36:01.199737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515896 | REC_0015366 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 10.6 | 67 | female | 1 | 25 | 5.3 | 2 | sotorasib 960 mg daily | 18.8 | true | MSI-H | 2026-03-15T05:36:01.200137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545448 | REC_0015367 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10.6 | 61 | male | 1 | 18 | 6.2 | 1 | osimertinib 80 mg daily | 18.2 | false | MSI-H | 2026-03-15T05:36:01.200762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806605 | REC_0015368 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 9.9 | 61 | female | 1 | 13 | 6.1 | 2 | entrectinib 600 mg daily | 20.9 | false | MSS | 2026-03-15T05:36:01.201199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552450 | REC_0015369 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.3 | 68 | female | 1 | 24 | 6.2 | 6 | pembrolizumab 200 mg q3w | 16.3 | false | MSS | 2026-03-15T05:36:01.201613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591009 | REC_0015370 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 9.8 | 72 | female | 2 | 8 | 7.8 | 4 | sotorasib 960 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:01.204630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300111 | REC_0015371 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 11.4 | 68 | female | 0 | 20 | 7.6 | 1 | alectinib 600 mg BID | 18.4 | true | MSS | 2026-03-15T05:36:01.205260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851224 | REC_0015372 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.7 | 54 | female | 0 | 11 | 5 | 5 | pembrolizumab 200 mg q3w | 11.3 | false | MSS | 2026-03-15T05:36:01.205739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909273 | REC_0015373 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.1 | 64 | female | 1 | 12 | 3.7 | 9 | alectinib 600 mg BID | 15.7 | false | MSS | 2026-03-15T05:36:01.206201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753352 | REC_0015374 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 2.5 | 59 | male | 1 | 12 | 8.2 | 5 | entrectinib 600 mg daily | 11.6 | true | MSS | 2026-03-15T05:36:01.206626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996544 | REC_0015375 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 11.4 | 59 | male | 0 | 9 | 6.9 | 2 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:36:01.207053+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871073 | REC_0015376 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 3.8 | 51 | female | 0 | 17 | 6.1 | 5 | pembrolizumab 200 mg q3w | 17.7 | false | MSS | 2026-03-15T05:36:01.207464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974956 | REC_0015377 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 7 | 75 | male | 2 | 22 | 8.1 | 2 | pembrolizumab 200 mg q3w | 14.7 | false | MSS | 2026-03-15T05:36:01.207852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210784 | REC_0015378 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 17.6 | 57 | female | 1 | 15 | 4.9 | 2 | entrectinib 600 mg daily | 30.6 | false | MSI-H | 2026-03-15T05:36:01.208513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607693 | REC_0015379 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.4 | 68 | female | 0 | 17 | 5.5 | 6 | entrectinib 600 mg daily | 15.5 | false | MSS | 2026-03-15T05:36:01.208959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254977 | REC_0015380 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 4 | 68 | female | 0 | 89 | 6 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.9 | true | MSS | 2026-03-15T05:36:01.209605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811792 | REC_0015381 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 16.7 | 69 | female | 1 | 14 | 4.9 | 2 | pembrolizumab 200 mg q3w | 15.6 | false | MSI-H | 2026-03-15T05:36:01.210067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324977 | REC_0015382 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 6.2 | 72 | female | 2 | 56 | 5.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 57.1 | false | MSS | 2026-03-15T05:36:01.210493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336003 | REC_0015383 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11 | 67 | female | 1 | 16 | 4.1 | 4 | entrectinib 600 mg daily | 5.9 | false | MSS | 2026-03-15T05:36:01.210886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614187 | REC_0015384 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 4.6 | 69 | male | 1 | 44 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 4.2 | false | MSS | 2026-03-15T05:36:01.211316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910968 | REC_0015385 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 11.9 | 72 | female | 1 | 9 | 4.5 | 6 | sotorasib 960 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:36:01.211714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232930 | REC_0015386 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 11.1 | 68 | female | 1 | 7 | 4.5 | 1 | alectinib 600 mg BID | 19.9 | false | MSI-H | 2026-03-15T05:36:01.212208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870849 | REC_0015387 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 14.1 | 73 | female | 2 | 18 | 5.4 | 1 | osimertinib 80 mg daily | 38.9 | true | MSS | 2026-03-15T05:36:01.212660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845320 | REC_0015388 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.3 | 69 | female | 1 | 25 | 3.3 | 5 | sotorasib 960 mg daily | 18.3 | true | MSS | 2026-03-15T05:36:01.213068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885491 | REC_0015389 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14.2 | 64 | male | 0 | 16 | 7.8 | 8 | osimertinib 80 mg daily | 12.9 | true | MSS | 2026-03-15T05:36:01.213440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549377 | REC_0015390 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 10.5 | 70 | male | 1 | 18 | 6.2 | 1 | alectinib 600 mg BID | 10.5 | true | MSI-H | 2026-03-15T05:36:01.213793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688137 | REC_0015391 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.9 | 76 | male | 1 | 18 | 4.5 | 2 | sotorasib 960 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:36:01.214154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132801 | REC_0015392 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.7 | 72 | female | 1 | 15 | 6.8 | 6 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:01.214533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585830 | REC_0015393 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 16.2 | 63 | male | 1 | 11 | 5.7 | 1 | pembrolizumab 200 mg q3w | 28.7 | true | MSS | 2026-03-15T05:36:01.217241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922734 | REC_0015394 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 9.7 | 80 | female | 2 | 23 | 6.1 | 6 | pembrolizumab 200 mg q3w | 17.7 | true | MSS | 2026-03-15T05:36:01.218323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402973 | REC_0015395 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.1 | 72 | female | 3 | 44 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 5 | false | MSS | 2026-03-15T05:36:01.218883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717181 | REC_0015396 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 8.9 | 61 | male | 0 | 16 | 2.8 | 2 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:36:01.219339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321606 | REC_0015397 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12 | 60 | male | 0 | 19 | 4.5 | 8 | osimertinib 80 mg daily | 18.6 | false | MSI-H | 2026-03-15T05:36:01.219766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624409 | REC_0015398 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 12.8 | 62 | female | 0 | 7 | 5.4 | 0 | osimertinib 80 mg daily | 46.4 | false | MSS | 2026-03-15T05:36:01.220298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981823 | REC_0015399 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 2.5 | 67 | female | 1 | 15 | 5.5 | 2 | pembrolizumab 200 mg q3w | 24.1 | false | MSS | 2026-03-15T05:36:01.221380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640060 | REC_0015400 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.5 | 66 | female | 1 | 21 | 3.4 | 6 | sotorasib 960 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:36:01.222610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.